Cargando…

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to targeted inhibitors in other settings is common; elucidating potential mechanisms of rux resistance in JAK2r B-ALL will...

Descripción completa

Detalles Bibliográficos
Autores principales:	Downes, Charlotte E. J., McClure, Barbara J., Bruning, John B., Page, Elyse, Breen, James, Rehn, Jacqueline, Yeung, David T., White, Deborah L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355279/ https://www.ncbi.nlm.nih.gov/pubmed/34376782 http://dx.doi.org/10.1038/s41698-021-00215-x

Ejemplares similares

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies
por: Downes, Charlotte EJ., et al.
Publicado: (2022)

Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis
por: Heatley, Susan L., et al.
Publicado: (2022)

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Eadie, Laura N., et al.
Publicado: (2023)

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
por: Flex, Elisabetta, et al.
Publicado: (2008)

Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia
por: Mäkinen, Ville-Petteri, et al.
Publicado: (2022)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
por: Page, Elyse C., et al.
Publicado: (2023)

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)
por: Rehn, Jacqueline, et al.
Publicado: (2022)

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients
por: Thomson, Ashlee J., et al.
Publicado: (2023)

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M.P., et al.
Publicado: (2017)

JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia
por: Bodaar, Kimberly, et al.
Publicado: (2022)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
por: Roncero, A M, et al.
Publicado: (2016)

Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia
por: Li, Qian, et al.
Publicado: (2017)

PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression
por: Yuan, Shengnan, et al.
Publicado: (2021)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

JAK-STAT in Early Hematopoiesis and Leukemia
por: Fasouli, Eirini Sofia, et al.
Publicado: (2021)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia
por: de Bock, Charles E., et al.
Publicado: (2018)

Epigenetic silencing of SOCS5 potentiates JAK‐STAT signaling and progression of T‐cell acute lymphoblastic leukemia
por: Sharma, Nitesh D., et al.
Publicado: (2019)

P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION
por: Courtois, Lucien, et al.
Publicado: (2023)

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia
por: Zhang, Qi, et al.
Publicado: (2018)

The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling
por: Cheng, Zhao, et al.
Publicado: (2017)

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase
por: Chakraborty, S, et al.
Publicado: (2013)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility
por: Lin, Minhui, et al.
Publicado: (2019)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

The Jak Tree
Publicado: (1889)

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
por: Delgado-Martin, C, et al.
Publicado: (2017)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review
por: Ogasawara, Toshie, et al.
Publicado: (2020)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
por: Gao, Jiapei, et al.
Publicado: (2023)

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
por: Ferrao, Ryan D, et al.
Publicado: (2018)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

A Novel Homozygous Nucleotide Deletion in the JAK2 Gene in a Pediatric Patient with B-cell Precursor Acute Lymphoblastic Leukemia
por: Akın, Dilara Fatma, et al.
Publicado: (2012)

Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations
por: Wong, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r40qbrf55ivj94tc33mlqg6ptf